i'm meg tirrell in chicago. >>> and that breast cancer study that meg just referenced was funded in part by the postal service. yup, proceeds from the breast cancer stamp put researchers over the top financially when they were trying to get enough money to do the landmark study. the american cancer society said without that stamp money, the study may never have been done. >>> coming up, a health care job that's in big demand. >>> more and more baby boomers are choosing to age at home and that's creating a boom in home health care. we'll tell you about it on "nightly business report." >>> global airlines are cutting the profit outlook, this as fuel costs rise. the international air transport association is warning that higher interest rates and geopolitical troubles will add to the risk. the global economy will lift passenger yields which is seen as a proxy for airfares. it will be the first annual gain since 2011. >>> well, the u.s. economy created a lot of jobs last month. as we reported on friday, a bulk of those positions came from the health care sector and demand for health care wor

offers presorted doses of medicine and home delivery it did send pharmaciy stocks tumbling today meg tirrellwatching these guys for a while meg? >> absolutely. this has been an ongoing question, what amazon will do in this space there were rumblings that amazon had required licenses to move into the pharmaceutical space. that affected not just cvs and walgreens and rite aid that are getting hit today. pharmacy benefits managers, express scripts, cvs caremark and united health have been really roped into these questions. amazon didn't have those pharmacy licenses. the licenses they had in health care were for their existing businesses that they were already in now it appears that with this acquisition, the terms of which weren't disclosed and appear to be less than $1 billion, amazon may have obtained the licenses they needed to do this in all 50 states that is a major part of this deal and everybody today is saying that the signals that amazon has put its flag down in the pharmacy space the question now is what is it going to do. carl >> meg, what is amazon really buying here? one of the int

meg tirrell has tonigci's modern me. >> rita perkin has lost more than half her body weight. she lost 100 pounds, but the scales were stuck as she couldn't stick on healthy habits. then she received a different prescription, a prescription for fresh, healthy food. >> we're standing in the fresh food pharmacy at the hospital. >> hi, rita. >> perkins is part of a new program designed to control type 2 diabetes in low-income patient. not with more medicine, but with food and education. >> in health care, we spend an awful lot on drugs and devices. becae it's business, but we spend a very small amount on preventive medicine. >> sort of like we're sidown and backwards. therogram has result indeed dramatic improvements in patients' health. some have been able to reduce yew ofdi ne, and it saves money, too. >> financially we have seen probably a decrease in health care claims paid o on our patients by over two thirds. >> this is the pdce i u to eat on. now i am down to this size. >> perkins receives ten frees me week for everybody in her household. it helped her drop another 45 poun

our meg tirrell at asco in chicago.my, ibb, 2% year to date. >> i heard what stephanie said, and it looks like this group, i think, is ready for another leg. i think it's bottoming i think rejen ron is one you have to be in. >> the number one name in the group for you? >> for me, and gen 2 because of the migraine drug everyone is raving about >> immu. this is one they rolled up calls in here. they have a deal with clovis oncology so since neck tar was such a slam to the downside - >> wow >> these guys have some breakthroughs coming in breast cancer so i would say iimu. >> i don't own any biotech now >> why not >> i sold for a gain, i just kind of find value elsewhere i think the medical device industry is much more attractive at this point. i own a big slog of baxter, but i like zimmer as an up and tot. >> i thought the data over the weekend was compelling if i am going anywhere would be that one and i have been buying johnson and johnson and not on this kind of play though >> sgood you mentioned that. i never seen j.j.

for "nightly business report," i'm meg tirrell in minneapolis. >>> college kids are mining bitcoin and doing it in their dorm rooms. >>> chicago has picked elan musk's boring company to build a hi-speed connect network connecting downtown to o'hare. it would carry -- and musk speaking alongside chicago's mayor says he's ready for this challenge. >> one of the hardest things to ith any new technology is not to demonstrate and show that it works, but to show people that can be indeed be useful. it's one of the hardest things in the world to make something e useful, the revenue exceeds the costs of the thing that was done. this is a deceer an an outstandingly different and unappreciated thing. that's what we intend to do here in chicago. >>> the link is expected to cut travel time down to 12 minutes. wow. >>> the s.e.c.'s point man on cryptocurrency says bitcoin is not a security the key t determining whether something is a security is the expectation of return by third party. until that definition, the s.e.c.ays bitcoin is not a security, because it's ra deceze many that sent bitcoin pri

meg tirrell is in chicago where she's been covering the conference she joins us now with a special guestg. >> good morning, joe this special guest is the ze celgene ceo. two biggest news of the conference came from zecelgene. both of these are in these personalized amino therapy treatments trying to help patients that have run out of other options in treating their cancers. let's start with the bluebird announcement some said those results, they were good, but didn't hit our expectations you're seeing bluebirade down a little bit today. how do you look at that? >> i think there's an expectation that we're going to cure mrefractory myeloma >> meaning it topp eped respondg >> to put that in context, that means a myeloma patient who's probably had the disease for more than ten years, in that context to have one year of progression-free survival would be unprecedented what investors were focused on is maybe it would be more durable than that. we don't understand the disconnect existing therapy in that setting, medium progression for survival through four months this is tripling what is avail

regulators making historic decision on one of its drugs just yesterday meg tirrell joins us with thels >> it was a major milestone, the first fda-approved medicine derived from the cannabis plant. the agency cleared the drug yesterday two days ahead of schedule to treat seizures associated with two rare forms of childhood epilepsy. the active ingredient is cbd, a purified distance derived from marijuana. it's not the chemical that produces a high. still, cbd is currently designated a schedule 1 substance by the drge ug enforcement agency cowen research estimates the medicine could draw more than $1 billion in annual revenue by 2022, assuming it's used by almost a quarter of kids with epilepsy who don't get enough benefit from existing medicines. it's a big leap, mel >> absolutely. meg. >>> first on cnbc is justin gover the ceo of gw pharmaceuticals. justin, great to have you with us >> thank you for having me back on the show. >> meg had just outlined a certain sort of key dates in terms of the timine of the launch of epidiolox. is there any reason to believe there will be a delay? t

dave ricks and meg tirrell >>> when we come back, check out the chart.s a pricing. >>> when we come back, check out the charts, an e-retailer, up 2 211% in 12 months. it's not amazon. according to the founder, he took the name from the italian phrase, meaning oh, yes. we'll reveal the stock and the growth straight ahead on "power lunch. f time to launch thousands of attacks. luckily security analysts and watson are on his side. spotting threats faster and protecting his data with the most securely encrypted main frame in the world. it's a smart way to eat lunch in peace. sweet, oblivious peace. it's a smart way to eat lunch in peace. with the new chase ink business unlimited card i get unlimited 1.5% cash back. it's so simple, i don't even have to think about it. so i think about the details. fine, i obsess over the details. introducing chase ink business unlimited with unlimited 1.5% cash back on every purchase. >>> time for trading nation now. reveal the mystery chart, etsy, soaring 30% to an all-time high today, and if you were puzzled by the clue, th

stocks in focus today with the world's largest cancer research conference under way in chicago our meg tirrell blueprint medicine ceo jeff albers meg, take it away. >> mel, thanks so much jeff, thanks for being with us >> thanks for having me on it's an exciting day for us. as you saw, we announced an important collaboration in china earlier today, and we think this is something that really can move us forward in an important area that last time i was on, we talked about the fact that blueprint's interested in partnerships that can either expand or accelerate access, and we think this collaboration can do that. >> well, i want to talk with you about that, but i also want to talk with you about some of the cancer research data being presented here you guys work in these genetically defined cancer drugs and really small patient populations where you hope the drugs will work really well for the patients that you've really tailored them to and you have a competitor which presented some data here at the conference. people are comparing those results right now. their response rate, 77%, yours is 50%

and trading health care before one of the biggest industry events of the year, our meg tirrell will beames you need to know about that's all at noon carl, that means we're less than 15 away. see you in a bit. >> see you then scott, thanks. >>> meantime, let's get to rick santelli what a morning get the santelli exchange. >> unbelievable morning. i see 289 in exchanchange we're down several basis points on the week. when you consider we had a settlement this week of 2.78%, it's a rather incredible week. may jobs report was solid. if we look at it, 223,000 jobs, much more than anybody is expecting. if we look at the unemployment rate, 3.8, average all the earnings, they were pretty good. what bothered me was that the pool of workers that are not counted anymore -- we'll call those the permanently unemployed they have the ability to work but they're not working. that reached 95.9 million. if you look at the unemployment rate of 3.8%, that implies 6.1 million unemployed which means we have 102 million people that we need to work along with to create better opportunity. now, i talked with e

i'm meg tirrell. we've got a news update for you on kia motors.ar is recalling more than 500,000 vehicles in the united states because of a glitch that may keep air bags from deploying in the event of a crash. this recall follows a federal investigation into four deaths and six injuries involving vehicles made by kia and hundred dahundre -- hyundai. >> meg, thank you. >>> chef, author, and television host anthony bourdain found dead in his hotel room in france of an apparent suicide. he was 61 years old. robert frank joins us now with a look at the life of anthony bourdain >> he was called a celebrity chef but like everything else in his life, anthony bourdain defied convention when it came to his brand and his business. after a troubled youth with drug addiction and lots of financial troubles, he worked his way through various new york kitchens and eventually rose to become executive chef, but his big break came when he was 44 and that book "kitchen confidential" was started as an article in the "new yorker," became a best seller in 2000, selling

meg tirrell is there and joins us now with the ceo of astrazeneca. >> jon, thank you very much.ascal, thank you for joining us. >> thank you it's a pleasure to be here as always. >> some of the biggest data has been in immunotherapy to better fight cancer you have a drug in this space. you're competing with bristol, roche and others how would you say you're competitively situated there >> there are two hours that are developing rapidly immunotherapy field the merck team has done a beautiful job and are clearly leading in that metastatic stage of lung cancer. if you are diagnosed at stage one, two or even three, you're not metastatic, so you have a chance to be cured stage four it's unlikely you're going to be cured. our focus has been on stage three with our product and we're reporting because we've got the data recently but we announced we've achieved survival benefit and there you can start to talk about curative intent. >> we have to be less afraid to use the word cure in cancer because there are certain situations where it's now appropriate and he mentioned lung cancer as on

a point that while pill pack is in networks now, that may not always necessarily be the case >> meg tirrell, thank you. >>> luke capital markets raising it price target. shares already up 40% this year. on the news line is the analyst who made that call anthony, great to have you with us you raised the price target in advance of this deal what do you think of this deal and what could amazon deal with this particularly when they have that joint venture with berkshire hathaway and jpmorgan? >> sure. so we see this deal as a trojan force. amazon is able to snap its finger and now has licenses to distribute drugs in all 50 u.s. states, which a lot of people thought it would take them years to do if they had to do it on a state by state basis pill pack doesn't move the needle much for amazon in the near term, but it is about the relationships, about the licenses, about the technology and so we really think that this is a shot across the bow for the retail drug chains as well as pbms >> did they buy the right company? sounds like they really zeroed in on one that could help. it is not a big compa

we'll follow-up on that and let's see what meg tirrell had to say >> we talk about commodities today. we don't talk much about copper. it has been strong take a look at freeport-mcmoran. i think there is plenty of upsides right now. >> bgcp, about a 10,000 lot just went off in there. i followed it during the show so i am in that right now >> bgcp. >> when i looked at you you were not paying attention, you were making a trade >> exactly >> i was watching him do it. >> excuse me, i have to make some trade >> he didn't say anything. he was typing away >> um, service now, this is a name that i mentioned before i am in the stock. pull back very nicely in may to the 50 h f day bounce off of that it did not bounce back its got a nice pattern of highs and lows >> roku is on a tear here. i like it. >> it is up 6% >> twilio which is my rocket fuel they continue to stay long keep on getting short. >> thanks guys >> you are my rocket fuel, scott. >> this is my rocket fuel. >> we are bringing the rocket fuel welcome everybody, i am tyler mathisen, here is what's on the menu today mystery in t hist

meg tirrell follows the money and gets you ahead of the trades >> good to see you the best place in theld to check on progress in treating cancer the updates at the conference can also cause major stock swings loxo soared 50% in one day, and the drug responsible for the move is now in front of the fda for review the company has another medicine in development with a similar strategy that already caught wall street's attention in the initial data release two weeks ago. along with shares of blueprint medicines which is developing a competing drug focused on the same target. even sooner than that, tonight, the stocks to watch are cellgene and bluebird bio they're highly anticipating the update coming out tonight at 6:00 p.m. eastern, and we'll get to talk with the ceo of loxo among with others on "the halftime report. >> what do you think of this space? as we said, this is always a market mover how should our viewers be thinking about this today? >> if you know what you're doing, it's a phenomenal space if you don't know what you're doing, you can still buy a basket or one of the etfs and

biotech stocks are in focus as well as the world's largest cancer research conference kicks off our meg tirrells heading to the conference shortly but joins us on what we should be watching for. >> i'm headed to chicago along with more than 39,000 attendees who are working in cancer research the sheer amount of information that we get at this conference, which is called the american society of clinical oncology or asco meeting, means there are also some major stock moves that come out of weekend. one category investors are focused on are targeted therapies. that area has seen a lot of success recently, and investors are closely watching two companies over the weekend for an update on saturday. loxo oncology and blueprint medicines, both small biotechs are focused on the same target and loxo's initial data caught investors' attention last week we'll have information next wednesday, including blueprint's on "power lunch. others will have updates in the hot space of immunotherapy we'll get some of the first highly anticipated data from celgene and bluebird bio that news is expected at 6:00 p.m. ea

executive edge the world's largest cancer research conference kicks off in chicago this weekend meg tirrelleaded that way. she joins us with a preview. a couple weeks ago i asked whether you were talking about asco i asked about asco, now it's th real one >> that was the lead up to asco. >> what's a good word for a nerd or a geek? what do you prefer this is exciting, is it not? >> it is i like either of those words >> nerd or geek. dork it all gets summarized what happened in the last year. it's a breakneck pace. >> so much information more than $39,000, cancer researchers, investors and analysts are heading to the asco meeting, our annual check in on how much progress has been made on treating cancer immuno-oncology drugs continue to dominate. those use our immune systems to treat. as soon as tonight we'll get some of the first data in immuno therapy from celgene and bluebird bio they are working on a therapy that modifies a patient's cells outside their own body and returns them to fight the cancer over the weekend we'll very more details including from loxo oncology, it was a major winne